Therapeutic approaches for T790M mutation positive non-small-cell lung cancer.

Therapeutic approaches for T790M mutation positive non-small-cell lung cancer. Expert Rev Anticancer Ther. 2018 Aug 06;: Authors: Attili I, Karachaliou N, Conte P, Bonanno L, Rosell R Abstract INTRODUCTION: Epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) is a subset of lung cancer with demonstrated response to targeted therapies. However, resistance to the first targeted approach usually occurs within the first year, and it is associated in 50-60% of cases to the T790M resistance mutation. Areas covered: The review provides an overview on the significance of the presence of the T790M mutation, its detection, treatment options and subsequent mechanisms of resistance. Expert commentary: Osimertinib is the current treatment option for T790M mutation positive NSCLC after progression to first or second-generation EGFR TKIs, with activity also on brain metastasis. However, the scenario is in continuous evolution and results from clinical trials are awaited in first line setting and in combination strategies. PMID: 30079781 [PubMed - as supplied by publisher]
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research